𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease

✍ Scribed by Maurits E. L. Arbouw; Kris L. L. Movig; Jeroen P. P. van Vugt; Toine C. G. Egberts

Publisher
Springer
Year
2009
Tongue
English
Weight
44 KB
Volume
65
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term efficacy and safety of pramipe
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial
✍ J. Carsten Möller; Wolfgang H. Oertel; Jürgen Köster; Gianni Pezzoli; Leandro Pr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract A double‐blind, placebo‐controlled study with a subsequent open‐label phase was conducted in 354 patients with Parkinson's disease (PD) and motor fluctuations under individually adjusted therapy with levodopa. During the double‐blind phase 174 patients received pramipexole and 180 place

Reply: Levodopa in the treatment of Park
Reply: Levodopa in the treatment of Parkinson's disease: Current controversies
✍ C. Warren Olanow; Yves Agid; Yoshi Mizuno 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

## Abstract The original articles to which this Letter refers have published in __Movement__ Disorders: Current Controversies: Levodopa in the Treatment of Parkinson's Disease, by Sharma, Vassallo, and Ross and Levodopa in the Treatment of Parkinson's Disease: Current Controversies, by Gerlach, Rei